Regulatory effects of Y4 receptor agonist (BVD-74D) on food intake.
The objective of this study was to clarify the role of a novel agonist with high selectivity and affinity for Y4 receptors in the regulation of food intake. The Y4 receptor agonist BVD-74D was administered to C57BL/6J mice that were fed with a normal or high-fat diet, and to fatty liver Shionogi (FLS)-ob/ob mice; the food intake, water intake, and body weight gain were measured in these mice. In the mice fed with a normal diet, the cumulative food intake significantly decreased at 20 min and 1 h after the administration of 1 mg/kg of BVD-74D and at 1, 2, 4, 8, and 24 h after the administration of 10 mg/kg of BVD-74D. Moreover, the cumulative water intake and body weight gain significantly decreased in these mice. Among the mice that were fed with a high-fat diet, the cumulative food intake and water intake significantly decreased 1, 2, and 4 h after BVD-74D (10 mg/kg) administration. Furthermore, the cumulative food intake significantly decreased 2 and 4 h after BVD-74D (10 mg/kg) administration in the FLS-ob/ob mice. Thus, we propose that the novel Y4 receptor agonist BVD-74D has suppressive effects on food intake, water intake, and weight gain in normal mice fed with normal diets and on food intake in normal mice fed with high-fat diets and in FLS-ob/ob mice. These findings indicate that the Y4 receptor and its agonist would be promising targets for obesity.
Li
Jiang-Bo
JB
Division of Psychosomatic Internal Medicine, Department of Social and Behavioral Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, 8-35-1 Sakuragaoka, Kagoshima, 890-8520, Japan.
Asakawa
Akihiro
A
Terashi
Mutsumi
M
Cheng
KaiChun
K
Chaolu
Huhe
H
Zoshiki
Takahiro
T
Ushikai
Miharu
M
Sheriff
Sulaiman
S
Balasubramaniam
Ambikaipakan
A
Inui
Akio
A
D000818:Animals; D019440:Anti-Obesity Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001007:Anxiety / Q000139:chemically induced; D001067:Appetite Depressants / Q000009:adverse effects / Q000627:therapeutic use; D001069:Appetite Regulation / Q000187:drug effects*; D001522:Behavior, Animal / Q000187:drug effects; D004041:Dietary Fats / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D004326:Drinking / Q000187:drug effects; D005234:Fatty Liver / Q000188:drug therapy; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D009765:Obesity / Q000188:drug therapy*; D010455:Peptides / Q000009:adverse effects / Q000627:therapeutic use*; D017476:Receptors, Neuropeptide Y / Q000819:agonists*; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects
D019440:Anti-Obesity Agents; D001067:Appetite Depressants; C554542:BVD-74D peptide; D004041:Dietary Fats; D010455:Peptides; D017476:Receptors, Neuropeptide Y; C109491:neuropeptide Y4 receptor